{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:50:37Z","timestamp":1780710637322,"version":"3.54.1"},"reference-count":67,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007675","name":"Collaborative Research Programme (CRP)\u2014International Centre for Genetic Engineering and Biotechnology (ICGEB)","doi-asserted-by":"publisher","award":["CRP\/BIH15-05"],"award-info":[{"award-number":["CRP\/BIH15-05"]}],"id":[{"id":"10.13039\/100007675","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative haematological malignancy characterized by constitutive activation of BCR-ABL1 tyrosine kinase in the majority of patients. BCR-ABL1 expression activates signaling pathways involved in cell proliferation and survival. Current treatment options for CML include tyrosine kinase inhibitors (TKI) with resistance as a major issue. Various treatment options for overcoming resistance are being investigated. Among them, phytochemical curcumin could play an important role. Curcumin has been found to exhibit anti-cancerous effects in various models, including CML, through regulation of multiple molecular signaling pathways contributing to tumorigenesis. We have evaluated curcumin\u2019s effects on imatinib-sensitive LAMA84S and K562, as well as imatinib-resistant LAMA84R cell lines. Our results indicate a significant dose-dependent decrease in cell viability and proliferation of imatinib-sensitive and imatinib-resistant cell lines after curcumin treatment. Suppression of key signaling molecules regulating metabolic and proliferative events, such as Akt, P70S6K and NF-kB, was observed. Increased expression of caspase-3 suggests the potential pro-apoptotic effect of curcumin in the imatinib-resistant CML model. Additional in silico molecular docking studies revealed binding modes and affinities of curcumin with different targets and the results are in accordance with in vitro findings. Altogether, these results indicate the potential role of curcumin in the treatment of CML.<\/jats:p>","DOI":"10.3390\/metabo13010058","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T03:50:32Z","timestamp":1672631432000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines"],"prefix":"10.3390","volume":"13","author":[{"given":"Esma","family":"Bilajac","sequence":"first","affiliation":[{"name":"Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasni\u010dka cesta 15, 71000 Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7358-5009","authenticated-orcid":false,"given":"Lejla","family":"Mahmutovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasni\u010dka cesta 15, 71000 Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-6990","authenticated-orcid":false,"given":"Una","family":"Glamo\u010dlija","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Sarajevo, Zmaja od Bosne 8, 71000 Sarajevo, Bosnia and Herzegovina"},{"name":"School of Medicine, University of Mostar, Zrinskog Frankopana 34, 88000 Mostar, Bosnia and Herzegovina"},{"name":"Scientific-Research Unit, Bosnalijek JSC, Juki\u0107eva 53, 71000 Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4206-6177","authenticated-orcid":false,"given":"Amar","family":"Osmanovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Sarajevo, Zmaja od Bosne 8, 71000 Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altijana","family":"Hromi\u0107-Jahjefendi\u0107","sequence":"additional","affiliation":[{"name":"Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasni\u010dka cesta 15, 71000 Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8499-9891","authenticated-orcid":false,"given":"Murtaza M.","family":"Tambuwala","sequence":"additional","affiliation":[{"name":"Lincoln Medical School, University of Lincoln, Brayford Pool Campus, Lincoln LN6 7TS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza","family":"Suljagi\u0107","sequence":"additional","affiliation":[{"name":"3DBioLabs, FabLab B&H, University of Sarajevo Campus, Zmaja od Bosne 8, 71000 Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic Myeloid Leukemia: 2018 Update on Diagnosis, Therapy and Monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/sctm.17-0175","article-title":"Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment: Role of Stem Cells in Chronic Myeloid Leukemia","volume":"7","author":"Arrigoni","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic Myeloid Leukemia: The Paradigm of Targeting Oncogenic Tyrosine Kinase Signaling and Counteracting Resistance for Successful Cancer Therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The Molecular Biology of Chronic Myeloid Leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic Myeloid Leukemia\u2014Advances in Biology and New Approaches to Treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2147\/DDDT.S191303","article-title":"Chronic Myelogenous Leukemia, a Still Unsolved Problem: Pitfalls and New Therapeutic Possibilities","volume":"13","author":"Flis","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","article-title":"Imatinib Mesylate in Chronic Myeloid Leukemia: Frontline Treatment and Long-Term Outcomes","volume":"16","author":"Stagno","year":"2016","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_9","first-page":"357027","article-title":"Imatinib: A Breakthrough of Targeted Therapy in Cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"ref_10","first-page":"1248","article-title":"Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance: Commentary Re: A. N. Mohamed et al., The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations","volume":"9","author":"Marcucci","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of Imatinib-Resistant Patients with Chronic Myeloid Leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2014003","DOI":"10.4084\/mjhid.2014.003","article-title":"Second-generation tyrosine kinase inhibitors (TKI) as salvage therapy for resistant or intolerant patients to prior TKIs","volume":"6","author":"Breccia","year":"2014","journal-title":"Mediterr J. Hematol Infect. Dis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.seminhematol.2010.06.002","article-title":"Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?","volume":"47","author":"Jabbour","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.5581\/1516-8484.20110124","article-title":"Imatinib Resistance: A Review of Alternative Inhibitors in Chronic Myeloid Leukemia","volume":"33","author":"Bitencourt","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"724360","DOI":"10.1155\/2013\/724360","article-title":"Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells","volume":"2013","author":"Hamad","year":"2013","journal-title":"Stem Cells Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40259-013-0056-z","article-title":"Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)","volume":"28","author":"Abruzzese","year":"2014","journal-title":"BioDrugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamaoncol.2019.6390","article-title":"Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status","volume":"6","author":"Kenzik","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-46401-5_1","article-title":"Curcumin: The Indian Solid Gold","volume":"Volume 595","author":"Aggarwal","year":"2007","journal-title":"The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease"},{"key":"ref_21","first-page":"84","article-title":"Cancer Therapy with Phytochemicals: Evidence from Clinical Studies","volume":"5","author":"Hosseini","year":"2015","journal-title":"Avicenna J. Phytomed."},{"key":"ref_22","first-page":"2032","article-title":"A Review of Therapeutic Effects of Curcumin","volume":"19","author":"Noorafshan","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.7150\/ijbs.33710","article-title":"Potential Mechanisms of Action of Curcumin for Cancer Prevention: Focus on Cellular Signaling Pathways and MiRNAs","volume":"15","author":"Wang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20091","DOI":"10.3390\/molecules191220091","article-title":"The Chemistry of Curcumin: From Extraction to Therapeutic Agent","volume":"19","author":"Priyadarsini","year":"2014","journal-title":"Molecules"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1080\/10408398.2015.1077195","article-title":"Curcumin, an Active Component of Turmeric (Curcuma Longa), and Its Effects on Health","volume":"57","author":"Kocaadam","year":"2017","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1078155211416530","article-title":"Effect of Imatinib Therapy with and without Turmeric Powder on Nitric Oxide Levels in Chronic Myeloid Leukemia","volume":"18","author":"Ghalaut","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_27","first-page":"23","article-title":"Molecular Targets of Curcumin in Breast Cancer (Review)","volume":"19","author":"Song","year":"2018","journal-title":"Mol. Med. Report"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wan Mohd Tajuddin, W.N.B., Lajis, N.H., Abas, F., Othman, I., and Naidu, R. (2019). Mechanistic Understanding of Curcumin\u2019s Therapeutic Effects in Lung Cancer. Nutrients, 11.","DOI":"10.3390\/nu11122989"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mbese, Z., Khwaza, V., and Aderibigbe, B.A. (2019). Curcumin and Its Derivatives as Potential Therapeutic Agents in Prostate, Colon and Breast Cancers. Molecules, 24.","DOI":"10.3390\/molecules24234386"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.1002\/jcp.28072","article-title":"Curcumin as a Therapeutic Agent in Leukemia","volume":"234","author":"Kouhpeikar","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.3390\/molecules15107035","article-title":"Potential of the Dietary Antioxidants Resveratrol and Curcumin in Prevention and Treatment of Hematologic Malignancies","volume":"15","author":"Kelkel","year":"2010","journal-title":"Molecules"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Giordano, A. (2019). Tommonaro Curcumin and Cancer. Nutrients, 11.","DOI":"10.3390\/nu11102376"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Martinez-Castillo, M., Bonilla-Moreno, R., Aleman-Lazarini, L., Meraz-Rios, M.A., Orozco, L., Cedillo-Barron, L., Cordova, E.J., and Villegas-Sepulveda, N. (2016). A Subpopulation of the K562 Cells Are Killed by Curcumin Treatment after G2\/M Arrest and Mitotic Catastrophe. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165971"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"21918","DOI":"10.18632\/oncotarget.4204","article-title":"Curcumin Inhibits in Vitro and in Vivo Chronic Myelogenous Leukemia Cells Growth: A Possible Role for Exosomal Disposal of MiR-21","volume":"6","author":"Taverna","year":"2015","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1182\/blood.V104.11.4685.4685","article-title":"Effect of the Combination of Imatinib Mesylate (Glivec) and Curcumin in Chronic Myeloid Leukemia Cell Line","volume":"104","author":"Kim","year":"2004","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcc.23899","article-title":"New Ways to Boost Molecular Dynamics Simulations","volume":"36","author":"Krieger","year":"2015","journal-title":"J. Comput. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/bioinformatics\/btu426","article-title":"YASARA View\u2014Molecular Graphics for All Devices\u2014From Smartphones to Workstations","volume":"30","author":"Krieger","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0092-8674(00)81698-0","article-title":"Structure of an IkappaBalpha\/NF-KappaB Complex","volume":"95","author":"Jacobs","year":"1998","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"ra37","DOI":"10.1126\/scisignal.2002618","article-title":"An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt","volume":"5","author":"Lin","year":"2012","journal-title":"Sci. Signal."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.str.2012.07.013","article-title":"The Crystal Structure of the Catalytic Domain of the NF-\u039aB Inducing Kinase Reveals a Narrow but Flexible Active Site","volume":"20","author":"Bowman","year":"2012","journal-title":"Structure"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S1097-2765(02)00550-6","article-title":"Molecular Mechanism for the Regulation of Protein Kinase B\/Akt by Hydrophobic Motif Phosphorylation","volume":"9","author":"Yang","year":"2002","journal-title":"Molecular Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1074\/jbc.M109.040667","article-title":"Structural Basis of Human P70 Ribosomal S6 Kinase-1 Regulation by Activation Loop Phosphorylation","volume":"285","author":"Sunami","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/jcc.10349","article-title":"A Point-Charge Force Field for Molecular Mechanics Simulations of Proteins Based on Condensed-Phase Quantum Mechanical Calculations","volume":"24","author":"Duan","year":"2003","journal-title":"J. Comput. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1039\/B517914A","article-title":"Advances in Methods and Algorithms in a Modern Quantum Chemistry Program Package","volume":"8","author":"Shao","year":"2006","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/prot.20921","article-title":"MUSTANG: A Multiple Structural Alignment Algorithm","volume":"64","author":"Konagurthu","year":"2006","journal-title":"Proteins"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.21873\/anticanres.15135","article-title":"Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin","volume":"41","author":"Jang","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mu, H., Zhu, X., Jia, H., Zhou, L., and Liu, H. (2021). Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.643382"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1517\/13543776.2014.953056","article-title":"Current Perspectives on the Therapeutic Aspects of Chronic Myelogenous Leukemia","volume":"24","author":"Bhaskar","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Glamoclija, U., Mahmutovic, L., Bilajac, E., Soljic, V., Vukojevic, K., and Suljagic, M. (2022). Metformin and Thymoquinone Synergistically Inhibit Proliferation of Imatinib-Resistant Human Leukemic Cells. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.867133"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/01635581.2018.1380208","article-title":"Synergistic Induction of Apoptosis by Quercetin and Curcumin in Chronic Myeloid Leukemia (K562) Cells","volume":"70","author":"Taga","year":"2018","journal-title":"Nutr. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.20546\/ijcmas.2016.512.026","article-title":"Curcumin Boosts up the Efficacy of Imatinib Mesylate in Chronic Myelogenic Leukemia Cell Line K-562 by Modulation of Various Markers","volume":"5","author":"Mukherjee","year":"2016","journal-title":"Int. J. Curr. Microbiol. App. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bmc.2016.11.023","article-title":"A Novel Curcumin Derivative Which Inhibits P-Glycoprotein, Arrests Cell Cycle and Induces Apoptosis in Multidrug Resistance Cells","volume":"25","author":"Oliveira","year":"2017","journal-title":"Bioorganic Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/aps.2013.180","article-title":"Curcumin Derivative C817 Inhibits Proliferation of Imatinib-Resistant Chronic Myeloid Leukemia Cells with Wild-Type or Mutant Bcr-Abl in Vitro","volume":"35","author":"Wu","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/aps.2017.160","article-title":"C1206, a Novel Curcumin Derivative, Potently Inhibits Hsp90 and Human Chronic Myeloid Leukemia Cells in Vitro","volume":"39","author":"Fan","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"553","DOI":"10.17221\/7820-VETMED","article-title":"Effects of Curcumin in Combination with Cyclophosphamide on Canine Mammary Tumour Cell Lines","volume":"59","author":"Anlas","year":"2014","journal-title":"Vet. Med."},{"key":"ref_57","first-page":"e2331","article-title":"Anticancer Activity of Curcumin on Human Breast Adenocarcinoma: Role of Mcl-1 Gene","volume":"8","author":"Entezari","year":"2015","journal-title":"Iran. J. Cancer Preven."},{"key":"ref_58","first-page":"2381","article-title":"Curcumin and Paclitaxel Induce Cell Death in Breast Cancer Cell Lines","volume":"40","author":"Calaf","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1158\/1541-7786.MCR-05-0172","article-title":"Curcumin Affects Components of the Chromosomal Passenger Complex and Induces Mitotic Catastrophe in Apoptosis-Resistant Bcr-Abl-Expressing Cells","volume":"4","author":"Wolanin","year":"2006","journal-title":"Mol. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.13005\/ojc\/330503","article-title":"Synthesis, Structure-Activity Relationship, Docking and Molecular Dynamic Simulation of Curcumin Analogues Against HL-60 for Anti Cancer Agents (Leukemia)","volume":"33","author":"Eryanti","year":"2017","journal-title":"Orient. J. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12935-020-01335-3","article-title":"Association between TERT Gene Polymorphisms and Acute Myeloid Leukemia Susceptibility in a Chinese Population: A Case\u2013Control Study","volume":"20","author":"Tong","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12539-012-0048-6","article-title":"Molecular Docking Studies of Curcumin Natural Derivatives with DNA Topoisomerase I and II-DNA Complexes","volume":"6","author":"Kumar","year":"2014","journal-title":"Interdiscip. Sci. Comput. Life Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/1871530315666150316120458","article-title":"Curcumin Targets in Inflammation and Cancer","volume":"15","author":"Deguchi","year":"2015","journal-title":"EMIDDT"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1749-6632.2009.04731.x","article-title":"Effect of Curcumin on Nuclear Factor \u039aB Signaling Pathways in Human Chronic Myelogenous K562 Leukemia Cells","volume":"1171","author":"Reuter","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_65","first-page":"6777","article-title":"Curcumin Differentially Affects Cell Cycle and Cell Death in Acute and Chronic Myeloid Leukemia Cells","volume":"15","author":"Berumen","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10286020903264077","article-title":"Autophagic and Apoptotic Mechanisms of Curcumin-Induced Death in K562 Cells","volume":"11","author":"Jia","year":"2009","journal-title":"J. Asian Nat. Prod. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2174\/156652411798062395","article-title":"Nutritional Antioxidants and Adaptive Cell Responses: An Update","volume":"11","author":"Speciale","year":"2011","journal-title":"Curr. Mol. Med."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/1\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:48:41Z","timestamp":1760147321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/1\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["metabo13010058"],"URL":"https:\/\/doi.org\/10.3390\/metabo13010058","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}